carboplatin + inetetamab + paclitaxel + pertuzumab

This is a combination regimen consisting of four agents: - **Carboplatin** (a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells) - **Inetetamab** (a biosimilar monoclonal antibody to trastuzumab, targeting the HER2 receptor) - **Paclitaxel** (a taxane-class chemotherapeutic that stabilizes microtubules, inhibiting cell division) - **Pertuzumab** (a monoclonal antibody targeting a different epitope on the HER2 receptor than trastuzumab/inetetamab, blocking dimerization and downstream signaling) This combination is designed for the treatment of HER2-positive cancers—most commonly breast cancer—by combining cytotoxic chemotherapy with dual anti-HER2 targeted therapy. The dual blockade of HER2 by inetetamab and pertuzumab provides synergistic inhibition of tumor growth. Carboplatin and paclitaxel provide broad cytotoxic activity against dividing tumor cells.

Brand names

Carboplatin-Taxol

Other names

TCbIP regimenNeoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin